Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
3556 results:
1. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
[TBL] [Abstract] [Full Text] [Related]
2. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
Xu G; Zhou L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 49(4):628-636. PubMed ID: 39019792
[TBL] [Abstract] [Full Text] [Related]
3. PRMT1 promotes Warburg effect by regulating the PKM2/PKM1 ratio in non-small cell lung cancer.
Peng L; Zhao Y; Tan J; Hou J; Jin X; Liu DX; Huang B; Lu J
Cell Death Dis; 2024 Jul; 15(7):504. PubMed ID: 39009589
[TBL] [Abstract] [Full Text] [Related]
4. Orthotopic Models Using New, Murine lung Adenocarcinoma cell Lines Simulate Human Non-small cell lung cancer Treated with Immunotherapy.
Knott EP; Kim EY; Kim EQ; Freire R; Medina JA; Wang Y; Chen CB; Wu C; Wangpaichitr M; Conejo-Garcia JR; Lim DC
Cells; 2024 Jun; 13(13):. PubMed ID: 38994972
[TBL] [Abstract] [Full Text] [Related]
5. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.
Sen T; Takahashi N; Chakraborty S; Takebe N; Nassar AH; Karim NA; Puri S; Naqash AR
Nat Rev Clin Oncol; 2024 Aug; 21(8):610-627. PubMed ID: 38965396
[TBL] [Abstract] [Full Text] [Related]
6. Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.
Lara-Sáez I; Mencía Á; Recuero E; Li Y; García M; Oteo M; Gallego MI; Enguita AB; de Prado-Verdún D; A S; Wang W; García-Escudero R; Murillas R; Santos M
Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2322917121. PubMed ID: 38959035
[TBL] [Abstract] [Full Text] [Related]
7. The Evolving Scenario of ES-SCLC Management: From Biology to New cancer Therapeutics.
Trillo Aliaga P; Del Signore E; Fuorivia V; Spitaleri G; Asnaghi R; Attili I; Corvaja C; Carnevale Schianca A; Passaro A; de Marinis F
Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927637
[TBL] [Abstract] [Full Text] [Related]
8. Durable Objective Response to Lurbinectedin in small cell Bladder cancer with tp53 Mutation: A Molecular-Directed Strategy.
Moussa MJ; Khandelwal J; Wilson NR; Naik SA; Subbiah V; Campbell MT; Msaouel P; Singh P; Alhalabi O
Curr Oncol; 2024 Jun; 31(6):3342-3349. PubMed ID: 38920737
[TBL] [Abstract] [Full Text] [Related]
9. Next generation antimitotic β-carboline derivatives modulate microtubule dynamics and downregulate NF-κB, ERK 1/2 and phospho HSP 27.
Jash M; Ghosh S; Roy R; Mukherjee N; Sen S; Ghosh S
Life Sci; 2024 Aug; 351():122836. PubMed ID: 38879159
[TBL] [Abstract] [Full Text] [Related]
10. Activity of osimeRTInib in non-small-cell lung cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
Pizzutilo EG; Agostara AG; Oresti S; Signorelli D; Stabile S; Lauricella C; Motta V; Amatu A; Ruggieri L; Brambilla M; Occhipinti M; Proto C; Giusti R; Filetti M; Genova C; Barletta G; Gelsomino F; Bennati C; Siringo M; Di Fazio GR; Russano M; Montrone M; Gariazzo E; Roca E; Bordi P; Delmonte A; Scimone A; Belluomini L; Mazzoni F; Carta A; Pelizzari G; Viscardi G; Morgillo F; Gelibter A; Gori S; Berardi R; Cortinovis D; Ardizzoni A; Veronese SM; Sartore-Bianchi A; Giannetta LG; Cerea G; Siena S
ESMO Open; 2024 Jun; 9(6):103592. PubMed ID: 38878323
[TBL] [Abstract] [Full Text] [Related]
11. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways.
Zamanian MY; Golmohammadi M; Yumashev A; Hjazi A; Toama MA; AbdRabou MA; Gehlot A; Alwaily ER; Shirsalimi N; Yadav PK; Moriasi G
Cell Biochem Funct; 2024 Jun; 42(4):e4071. PubMed ID: 38863255
[TBL] [Abstract] [Full Text] [Related]
12. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-small cell lung cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract] [Full Text] [Related]
13. Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway.
Fu R; You Y; Wang Y; Wang J; Lu Y; Gao R; Pang M; Yang P; Wang H
Biochem Pharmacol; 2024 Aug; 226():116345. PubMed ID: 38852643
[TBL] [Abstract] [Full Text] [Related]
14. Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway.
Liao W; Zhang R; Chen G; Zhu X; Wu W; Chen Z; Jiang C; Lin Z; Ma L; Yu H
Biomed Pharmacother; 2024 Jul; 176():116832. PubMed ID: 38850659
[TBL] [Abstract] [Full Text] [Related]
15. Serial cell-Free DNA Sequencing in
Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
[TBL] [Abstract] [Full Text] [Related]
16. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
[TBL] [Abstract] [Full Text] [Related]
17. Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.
Yokota E; Iwai M; Ishida Y; Yukawa T; Matsubara M; Naomoto Y; Fujiwara H; Monobe Y; Haisa M; Takigawa N; Fukazawa T; Yamatsuji T
Hum Cell; 2024 Jul; 37(4):1132-1140. PubMed ID: 38829559
[TBL] [Abstract] [Full Text] [Related]
18. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
[TBL] [Abstract] [Full Text] [Related]
19. PIPET: predicting relevant subpopulations in single-cell data using phenotypic information from bulk data.
Ruan X; Cheng Y; Ye Y; Wang Y; Chen X; Yang Y; Liu T; Yan F
Brief Bioinform; 2024 May; 25(4):. PubMed ID: 38819254
[TBL] [Abstract] [Full Text] [Related]
20. Se-methylselenocysteine inhibits the progression of non-small cell lung cancer via ROS-mediated NF-κB signaling pathway.
Ge L; Liu P; Tian L; Li Y; Chen L
Exp Cell Res; 2024 Jul; 440(1):114101. PubMed ID: 38815788
[TBL] [Abstract] [Full Text] [Related]
[Next]
